% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • earfool earfool Mar 6, 2013 10:44 PM Flag

    Improved Progression-Free Survival in patients with short tumor telomere length:

    Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC


    Another Geron Multi-Center study AACR presentation
    Their findings suggested that imetelstat given as maintenance therapy did prolong progression free survival in patients with advanced NSCLC whose tumors have short telomeres. They report that these data are consistent with the hypothesis that clinical benefit from telomerase inhibition is greater in patients with tumors possessing short telomeres.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.85+0.04(+1.42%)May 27 4:00 PMEDT